ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Delinia debuts to tackle autoimmunity

by Lisa M. Jarvis
September 19, 2016 | APPEARED IN VOLUME 94, ISSUE 37

With $35 million in its first formal round of funding, Delinia has launched to develop treatments for severe autoimmune diseases. Atlas Venture and Sofinnova Partners led the funding, which will be used to push Delinia’s lead molecule through clinical studies. Whereas current autoimmune treatments primarily suppress the immune system, Delinia is trying to regulate immune response. The company’s lead compound, a biologic, is a selective agonist of the interleukin-2 receptor on liver-targeted regulatory T cells, which help maintain immune system balance.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment